{Reference Type}: Journal Article
{Title}: Protocol for treatment of constipation with polyethylene glycol 3350 plus electrolytes in critically ill children.
{Author}: López J;Barba MG;Fernández SN;Solana MJ;Urbano J;Sánchez C;López-Herce J;
{Journal}: An Pediatr (Engl Ed)
{Volume}: 99
{Issue}: 3
{Year}: 2023 Sep 26
暂无{DOI}: 10.1016/j.anpede.2023.05.009
{Abstract}: <B>OBJECTIVE: </B>No studies have analysed the effectiveness of treatment for constipation in critically ill children. The aim of this study was to assess the implementation, efficacy and safety of a treatment protocol using polyethylene glycol 3350 with electrolytes (PEG 3350 + E) for constipation in critically ill children.<BR><B>METHODS: </B>We conducted a single-centre prospective study in children admitted to the paediatric intensive care unit for a minimum of 72 h and who developed constipation. Children with previous gastrointestinal disorders or diseases were excluded. The patients were treated with rectal enemas or with the oral PEG 3350 + E protocol at the discretion of the treating physician. We compared clinical and demographic variables as well as adverse events (diarrhoea, abdominal distension and electrolyte imbalances).<BR><B>RESULTS: </B>The sample included 56 patients with a mean age of 48.2 ± 11.9 months, of who 55.4% were male. Forty-four patients (78.6%) were treated with PEG 3350 + E and 12 (21.4%) with rectal enemas. The proportion of patients that responded well to treatment was greater in the PEG 3350 + E group (79.5%) compared to the enema group (58.3%), but the difference was not statistically significant (P = .151). There were no significant differences between the groups in any of the adverse effects. Treatment with PEG 3350 + E was more effective in children aged less than 2 years (100%) compared to older children (100% vs 65.4%; P < .01), with no significant differences in the development of adverse events.<BR><B>CONCLUSIONS: </B>The PEG 3350 + E treatment protocol for constipation in critically ill children was effective and associated with few adverse events, even in children aged less than 2 years.